Group 1 - Invalda INVL has signed option contracts with employees for 24,008 ordinary registered shares, in accordance with the rules for Granting Equity Incentives and the resolution from the Annual General Meeting held on April 30, 2025 [1] - Employees will receive the shares free of charge in 2028, with a nominal value of EUR 0.29 per share [1] - If dividends or free funds are declared before the shares are granted in 2028, the number of shares will be recalculated based on a formula approved by the shareholders meeting [1] Group 2 - Since 2016, a total of 791,650 Invalda INVL shares have been subject to stock option agreements involving employees of the company and its group companies [2]

First half 2024–2025 results Priority given to reducing debt and optimizing WCR in the first half, positive net income driven by lower costs in response to lower volumes in Agricultural Spraying In the first half of 2024–2025, EXEL Industries's revenue fell 10.0% to €443.4 million.The Group posted half-year recurring EBITDA of €20.3 million, representing 4.6% of revenue.Net income was positive at €1.5 million.The Group's level of net financial debt improved by €38 million compared with last year, as a res ...

Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the results of the votes of its Combined Shareholders’ Meeting. The Combined Shareholders' Meeting was held on Thursday May 22, 2025, at 9 a.m. at Hôtel Villa M, 24-30 Bd Pasteur, 75015 Paris (Fra ...

 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION,DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE IT IS UNLAWFULTO DO SO Flutter announces the pricing of $1,000 million aggregate principal amount of 5.875% Senior Secured Notes due 2031, €550 million aggregate principal amount of 4.000% Senior Secured Notes due 2031 and £450 million aggregate principal amount of 6.125% Senior Secured Notes due 2031 DUBLIN and TORONTO, May 23, 2025 (GLOBE NEWSWIRE) -- Flutter Entertainment plc ("Flutter") (NYSE:FLUT; LSE:FLTR), ...

Core Insights - Crédit Coopératif has signed a memorandum of understanding with Orange for the potential acquisition of fintech Anytime, aligning with its 2030 strategic plan "100% committed" [1][4] - The acquisition aims to enhance Crédit Coopératif's digital offerings, particularly for small and medium-sized associations, leveraging Anytime's innovative services [2][5] - Discussions initiated with Orange Bank are expected to support Anytime's evolution in the Social and Solidarity Economy markets [3][4] Company Overview - Crédit Coopératif is a cooperative bank focused on environmental and social transitions, serving clients such as cooperatives, SMEs, and non-profit organizations [7] - The bank aims to strengthen its presence in the association market and achieve a market share of over 6% among newly created associations by 2030 [8] Strategic Goals - The acquisition of Anytime is part of a broader strategy to build a 100% digital offering tailored to small associations [8] - Crédit Coopératif plans to enhance dedicated services for large Social and Solidarity Economy organizations, including advanced expense management tools [8] Anytime Overview - Founded in 2014 and a subsidiary of Orange Bank since 2020, Anytime specializes in account management and payment services for professionals and associations [5] - The fintech has developed tailored solutions for associations, including advanced expense management tools [5] Social Process - Employee representative bodies within both the Orange Group and Crédit Coopératif are being consulted regarding the acquisition, with a potential completion date set for the end of 2025 [6]

Disclosure of trading in own shares occurred from May 19 to May 22, 2025 Saint-Cloud, May 23, 2025 In accordance with the regulations on share buybacks, in particular Regulation (EU) 2016/1052, Elis hereby declares the purchases of its own shares made from May 19, 2025 to May 22, 2025 under the buyback program authorized by the 19th resolution of the General Shareholders' Meeting of May 23, 2024 and announced on March 6, 2025: Aggregated presentation: Issuer nameIssuer code(LEI) Transaction dateISIN CodeDai ...

Company Overview - AB Science S.A. is a pharmaceutical company founded in 2001, specializing in the research, development, and commercialization of protein kinase inhibitors (PKIs) [5] - The company is headquartered in Paris, France, and is listed on Euronext Paris under the ticker AB [5] - AB Science focuses on diseases with high unmet medical needs, including oncology, neurological diseases, inflammatory diseases, and viral diseases [5] Recent Capital Increase - AB Science announced a capital increase of €1.8 million, which was settled and delivered on May 23, 2025 [1] - This capital increase was subscribed by a limited number of investors and is expected to strengthen the company's cash position [2] Product Development - Masitinib is a novel oral tyrosine kinase inhibitor being developed to target mast cells and macrophages, with potential applications in oncology, inflammatory diseases, and central nervous system diseases [3] - AB8939 is a new synthetic microtubule-destabilizing drug candidate that shows broad anticancer activity and may overcome drug resistance associated with standard chemotherapies [4]

Core Points - Endeavour Mining plc announced that all resolutions at the annual general meeting held on May 22, 2025, were passed by shareholders [2][3] Voting Results - The resolution to receive the 2024 Annual Report received 99.99% approval with 176,125,066 votes for and only 24,217 against [2] - Alison Baker was re-elected as a Director with 97.86% approval, totaling 172,530,626 votes for and 3,781,331 against [2] - The re-election of Patrick Bouisset as a Director garnered 99.87% approval, with 176,089,288 votes for [2] - Ian Cockerill's re-election as a Director received 99.89% approval, totaling 176,092,874 votes for [2] - Cathia Lawson Hall was re-elected as a Director with 94.12% approval, receiving 165,943,922 votes for [2] - Livia Mahler's re-election as a Director received 98.70% approval, totaling 174,016,670 votes for [2] - Sakhila Mirza was re-elected as a Director with 99.96% approval, receiving 176,241,478 votes for [2] - John Munro's re-election as a Director received 99.98% approval, totaling 176,275,331 votes for [2] - Naguib Sawiris was re-elected as a Director with 99.88% approval, receiving 176,106,435 votes for [2] - Srinivasan Venkatakrishnan's re-election as a Director received 98.84% approval, totaling 174,262,580 votes for [2] - BDO LLP was reappointed as auditors with 99.98% approval, totaling 179,901,158 votes for [2] - The Directors' Remuneration Policy was approved with 81.67% approval, receiving 143,048,709 votes for [2] - The Directors' Remuneration Report received 98.53% approval, totaling 173,549,067 votes for [2] - The authority to purchase own shares received 99.98% approval, with 176,164,397 votes for [3] Company Overview - Endeavour Mining is one of the world's senior gold producers and the largest in West Africa, with operations in Senegal, Côte d'Ivoire, and Burkina Faso [5][6] - The company is committed to responsible mining and delivering value to society [6]

Core Viewpoint - Frontline plc reported its first-quarter results for 2025, indicating stable performance amidst economic and political uncertainties, with improvements in fleet utilization and a strong liquidity position [1][2][3]. Financial Performance - The company achieved a profit of $33.3 million, or $0.15 per share, with an adjusted profit of $40.4 million, or $0.18 per share for Q1 2025 [5]. - Revenues for the first quarter were reported at $427.9 million [5]. - A cash dividend of $0.18 per share was declared for the first quarter of 2025 [5]. Fleet and Operations - Average daily spot time charter equivalent (TCE) earnings for VLCCs, Suezmax tankers, and LR2/Aframax tankers were $37,200, $31,200, and $22,300 respectively in Q1 2025 [5]. - Fleet growth remains slow, with ordering stalling, which supports the long-term fundamentals for tankers [2]. Liquidity and Financing - The company has strengthened its liquidity through refinancings in 2025, with no significant debt maturities until 2030 [3]. - Entered into three senior secured credit facilities in February 2025 for up to $239 million and a senior secured term loan facility in April 2025 for up to $1,286.5 million [5]. Market Outlook - Spot TCEs for the full second quarter of 2025 are expected to be lower than currently contracted due to ballast days [4]. - Utilization on larger ships has improved, and there are healthy developments in activity across segments due to pressure on sanctioned trades [2].

Core Viewpoint - Roche has announced a strategic collaboration with Broad Clinical Labs to develop and pilot applications using Roche's next-generation sequencing (NGS) Sequencing By Expansion (SBX) technology, aiming to transform clinical genomics and biomedical discovery [1][5]. Group 1: Collaboration Details - The initial project will focus on trio-based whole genome sequencing for critically ill newborns and their biological parents, with the goal of making whole genome sequencing a routine part of clinical care in neonatal intensive care units (NICUs) [2][7]. - The collaboration aims to integrate SBX technology into clinical and translational pipelines, enhancing both routine clinical care and biomedical innovation [3][4]. Group 2: Technology Features - SBX technology offers ultra-fast turnaround times, exceptional scalability, and cost efficiency, making it suitable for a variety of genomic applications, including whole genome sequencing, whole exome sequencing, and RNA sequencing [3][9]. - The technology is designed to overcome limitations of traditional sequencing methods, providing high accuracy along with flexibility and speed [6][9]. Group 3: Organizational Background - Broad Clinical Labs, a subsidiary of the Broad Institute of MIT and Harvard, is a leader in human whole genome sequencing, having sequenced over 750,000 genomes [11]. - Roche, founded in 1896, is the world's largest biotechnology company and a leader in in-vitro diagnostics, committed to advancing precision medicine [12].